In a remarkable display of market confidence, Natera Inc . (NASDAQ:) stock has reached an all-time high, touching a price level of $175.68, with a robust market capitalization of $23 billion. According to InvestingPro data, the company’s strong financial health score and impressive revenue growth of ~55% highlight its market momentum. This milestone underscores a period of significant growth for the company, which has seen its stock value surge by an impressive 164.61% over the past year. Investors have rallied behind Natera’s innovative genetic testing solutions, propelling the stock to new heights and reflecting a strong endorsement of the company’s future prospects in the burgeoning field of personalized medicine. InvestingPro analysis reveals the company maintains a healthy current ratio of 4.39, indicating strong liquidity, though current valuations suggest the stock may be trading above its Fair Value. Discover 12 additional key insights about NTRA with an InvestingPro subscription, including detailed valuation metrics and growth projections.
In other recent news, Natera Inc., a genetic testing company, reported a 64% year-over-year increase in Q3 revenue, reaching a record $439.8 million. The company also conducted 137,000 oncology tests, marking a 54% rise from the previous year. These robust financial results led Natera to revise its full-year revenue guidance to between $1.61 billion and $1.64 billion.
In legal developments, Natera has expanded its patent infringement litigation against NeoGenomics (NASDAQ:), Inc. over the RaDaR test. The company is seeking comprehensive remedies, including injunctive relief against NeoGenomics’ current RaDaR test offering. However, Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:), though the company plans to request the court to overturn the ruling.
In terms of analyst ratings, TD Cowen reiterated a Buy rating on Natera shares, raising the price target from $175 to $195. Similarly, Baird and Jefferies also maintained positive ratings on Natera’s stock and increased their price targets.
Among other company news, Natera has amended an agreement with Dr. Rabinowitz, the Executive Chairman, to continue his role with certain conditions outlined in the agreement. These recent developments provide investors with insights into Natera’s current status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
